Directed phenotype switching as an effective antimelanoma strategy.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Cancer Cell

• Publication date

  2013-07-08

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.ccr.2013.05.009PMID 23792190
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.

  2012cited by this paper
• Hypoxia and MITF control metastatic behaviour in mouse and human melanoma cells

  2012cited by this paper
• Melanoma coordinates general and cell-specific mechanisms to promote methotrexate resistance.

  2012cited by this paper
• Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma

  2011influential reference
• The role of mitogen‐ and stress‐activated protein kinase pathways in melanoma

  2011cited by this paper
• Mitf is the key molecular switch between mouse or human melanoma initiating cells and their differentiated progeny

  2011cited by this paper
• Mitf is the key molecular switch between mouse or human melanoma initiating cells and their differentiated progeny

  2011influential reference
• Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma.

  2011cited by this paper
• Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options.

  2011cited by this paper
• Essential role of microphthalmia transcription factor for DNA replication, mitosis and genomic stability in melanoma

  2011cited by this paper
• Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

  2010cited by this paper
• Interferon-γ links UV to melanocyte activation and promotes melanomagenesis

  2010cited by this paper
• Fifteen‐year quest for microphthalmia‐associated transcription factor target genes

  2010influential reference
• Cancer stem cells versus phenotype‐switching in melanoma

  2010cited by this paper
• Lysine methylation regulates E2F1-induced cell death.

  2010cited by this paper
• The discovery of the microphthalmia locus and its gene, Mitf

  2010cited by this paper
• Genome‐wide analysis of POU3F2/BRN2 promoter occupancy in human melanoma cells reveals Kitl as a novel regulated target gene

  2010cited by this paper
• ATR and Chk1 Suppress a Caspase-3–Dependent Apoptotic Response Following DNA Replication Stress

  2009cited by this paper
• Melanoma activation of 3-o-(3,4,5-trimethoxybenzoyl)-(-)-epicatechin to a potent irreversible inhibitor of dihydrofolate reductase.

  2009cited by this paper
• Integrating BRAF/MEK inhibitors into combination therapy for melanoma

  2009cited by this paper
• The critical role of alpha‐folate receptor in the resistance of melanoma to methotrexate

  2009cited by this paper
• Intravital imaging reveals transient changes in pigment production and Brn2 expression during metastatic melanoma dissemination.

  2009cited by this paper
• Synthesis and biological activity of a 3,4,5-trimethoxybenzoyl ester analogue of epicatechin-3-gallate.

  2008cited by this paper
• Frequent somatic mutations of GNAQ in uveal melanoma and blue nevi

  2008cited by this paper
• Chk1 suppresses a caspase-2 apoptotic response to DNA damage that bypasses p53, Bcl-2, and caspase-3.

  2008cited by this paper
• The role of p53 in pigmentation, tanning and melanoma

  2008cited by this paper
• An E2F1-dependent gene expression program that determines the balance between proliferation and cell death.

  2008cited by this paper
• Cancer stem cells in solid tumours: accumulating evidence and unresolved questions

  2008cited by this paper
• γ-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin

  2008cited by this paper
• Brn-2 represses microphthalmia-associated transcription factor expression and marks a distinct subpopulation of microphthalmia-associated transcription factor-negative melanoma cells.

  2008cited by this paper
• How to make a melanoma: what do we know of the primary clonal events?

  2007cited by this paper
• Somatic activation of KIT in distinct subtypes of melanoma.

  2006cited by this paper
• Mitf regulation of Dia1 controls melanoma proliferation and invasiveness.

  2006cited by this paper
• Why Therapeutic Response May Not Prolong the Life of a Cancer Patient: Selection for Oncogenic Resistance

  2005cited by this paper
• p73-induced apoptosis: a question of compartments and cooperation.

  2005cited by this paper
• Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma

  2005cited by this paper
• Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression

  2005cited by this paper
• Chk1 and p21 cooperate to prevent apoptosis during DNA replication fork stress.

  2005cited by this paper
• Cancer chemotherapy by deoxynucleotide depletion and E2F-1 elevation.

  2005cited by this paper
• Migrating cancer stem cells — an integrated concept of malignant tumour progression

  2005cited by this paper
• MITF links differentiation with cell cycle arrest in melanocytes by transcriptional activation of INK4A

  2005cited by this paper
• Regulation in S Phase by E2F

  2004cited by this paper
• Differentiation of human melanoma cells induced by cyanidin‐3‐O‐β‐glucopyranoside

  2004cited by this paper
• p73 induction after DNA damage is regulated by checkpoint kinases Chk1 and Chk2.

  2004cited by this paper
• MLANA/MART1 and SILV/PMEL17/GP100 are transcriptionally regulated by MITF in melanocytes and melanoma.

  2003cited by this paper
• Mutations of the BRAF gene in human cancer

  2002cited by this paper
• Retinoblastoma Tumor Suppressor Targets dNTP Metabolism to Regulate DNA Replication*

  2002cited by this paper
• Apoptosis of haematopoietic cells upon thymidylate synthase inhibition is independent of p53 accumulation and CD95-CD95 ligand interaction.

  2001cited by this paper
• Selective induction of E2F1 in response to DNA damage, mediated by ATM-dependent phosphorylation.

  2001cited by this paper
• Direct Regulation of the Microphthalmia Promoter by Sox10 Links Waardenburg-Shah Syndrome (WS4)-associated Hypopigmentation and Deafness to WS2*

  2000cited by this paper
• Regulation of E2F1 activity by acetylation

  2000cited by this paper
• Alkaptonuria: such a long journey

  1996cited by this paper
• Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer.

  1995cited by this paper
• Analysis of N-ras mutations in human cutaneous melanoma: tumor heterogeneity detected by polymerase chain reaction/single-stranded conformation polymorphism analysis.

  1995cited by this paper
• Mutations at the mouse microphthalmia locus are associated with defects in a gene encoding a novel basic-helix-loop-helix-zipper protein.

  1993cited by this paper
• Tumor heterogeneity and the biology of cancer invasion and metastasis.

  1978cited by this paper

• CDC25A inhibition sensitizes melanoma cells to doxorubicin and NK cell therapy

  2025cites this paper
• A BRN2:MYC transcriptional axis regulates interconversion between therapy-resistant and tumorigenic phenotypes in melanoma

  2025cites this paper
• Pharmacological targeting of the cancer epigenome

  2024cites this paper
• Mitochondrial signatures shape phenotype switching and apoptosis in response to PLK1 inhibitors

  2024cites this paper
• LncRNAs in melanoma phenotypic plasticity: emerging targets for promising therapies

  2024cites this paper
• Ecological and evolutionary dynamics to design and improve ovarian cancer treatment

  2024cites this paper
• Pharmacogenetics in Oncology: A useful tool for individualizing drug therapy

  2024cites this paper
• Transglutaminase Type 2-MITF axis regulates phenotype switching in skin cutaneous melanoma

  2023cites this paper
• E-Cadherin Immunostaining in Equine Melanocytic Tumors

  2023cites this paper
• Ginsenoside Re inhibits melanogenesis and melanoma growth by downregulating microphthalmia-associated transcription factor.

  2023cites this paper
• The journey from melanocytes to melanoma

  2023cites this paper
• S-adenosylmethionine blocks tumorigenesis and with immune checkpoint inhibitor enhances anti-cancer efficacy against BRAF mutant and wildtype melanomas

  2023cites this paper
• Targeting protein methylation in pancreatic cancer cells results in KRAS signaling imbalance and inhibition of autophagy

  2023cites this paper
• Quantifying cancer cell plasticity with gene regulatory networks and single-cell dynamics

  2023cites this paper
• Scales of Cancer Evolution: Selfish Genome or Cooperating Cells?

  2022cites this paper
• Epigenetic factors in breast cancer therapy

  2022cites this paper
• The Genetic Basis of Dormancy and Awakening in Cutaneous Metastatic Melanoma

  2022cites this paper
• Integrative Genomic Profiling Uncovers Therapeutic Targets of Acral Melanoma in Asian Populations

  2022cites this paper
• Archetype tasks link intratumoral heterogeneity to plasticity and cancer hallmarks in small cell lung cancer.

  2022cites this paper
• Involvement of Epithelial–Mesenchymal Transition Genes in Small Cell Lung Cancer Phenotypic Plasticity

  2022cites this paper
• Connecting Metabolic Rewiring With Phenotype Switching in Melanoma

  2022cites this paper
• MITF induces escape from innate immunity in melanoma

  2021cites this paper
• Melanoma models for the next generation of therapies.

  2021cites this paper
• Cancer Hallmarks Define a Continuum of Plastic Cell States between Small Cell Lung Cancer Archetypes

  2021cites this paper
• Nanog maintains stemness of Lkb1‐deficient lung adenocarcinoma and prevents gastric differentiation

  2021cites this paper
• Melanoma Plasticity: Promoter of Metastasis and Resistance to Therapy

  2021cites this paper
• Modulating cell differentiation in cancer models.

  2021cites this paper
• Potential of star-shaped polymeric nanoparticles of poly(ε-carprolactone) and poly (lactic-co-glycolic acid) for drug delivery; A comparative study with linear analogs

  2021cites this paper
• The genetic and epigenetic basis of distinct melanoma types

  2021cites this paper
• Epigenetic mechanisms in breast cancer therapy and resistance

  2021cites this paper
• Reemergence of neural crest stem cell‐like states in melanoma during disease progression and treatment

  2020cites this paper
• Organotypic Models in Drug Development "Tumor Models and Cancer Systems Biology for the Investigation of Anticancer Drugs and Resistance Development".

  2020cites this paper
• Genomic profiling of a dedifferentiated mucosal melanoma following exposure to immunotherapy

  2020cites this paper
• The complex relationship between MITF and the immune system: a Melanoma ImmunoTherapy (response) Factor?

  2020cites this paper
• Deciphering Melanoma Cell States and Plasticity with Zebrafish Models

  2020cites this paper
• Persister state-directed transitioning and vulnerability in melanoma

  2020cites this paper
• Chloroacridine derivatives as potential anticancer agents which may act as tricarboxylic acid cycle enzyme inhibitors.

  2020cites this paper
• Non-genetic mechanisms of therapeutic resistance in cancer

  2020cites this paper
• EMT-Inducing Transcription Factors, Drivers of Melanoma Phenotype Switching, and Resistance to Treatment

  2020cites this paper
• T-type calcium channel inhibition restores sensitivity to MAPK inhibitors in de-differentiated and adaptive melanoma cells

  2020cites this paper
• Bidirectional interconversion between mutually exclusive tumorigenic and drug-tolerant melanoma cell phenotypes

  2020cites this paper
• Epithelial-Mesenchymal Transition in Skin Cancers: A Review

  2019cites this paper
• MITF controls the TCA cycle to modulate the melanoma hypoxia response

  2019cites this paper
• Adaptive Responses as Mechanisms of Resistance to BRAF Inhibitors in Melanoma

  2019cites this paper
• Sequential transcriptional waves and NF-κB-driven chromatin remodeling direct drug-induced dedifferentiation in cancer

  2019influential citation
• Melanoma plasticity and phenotypic diversity: therapeutic barriers and opportunities

  2019influential citation
• The great escape: tumour cell plasticity in resistance to targeted therapy

  2019cites this paper
• Lineage-Restricted Regulation of SCD and Fatty Acid Saturation by MITF Controls Melanoma Phenotypic Plasticity.

  2019cites this paper
• Starvation and Pseudo-Starvation as Drivers of Cancer Metastasis through Translation Reprogramming.

  2019cites this paper
• Comparison of Xiphophorus and human melanoma transcriptomes reveals conserved pathway interactions

  2018cites this paper
• Novel therapeutic compound acridine–retrotuftsin action on biological forms of melanoma and neuroblastoma

  2018cites this paper
• Nonallergic cutaneous pigmentation is commonly observed after methotrexate administration

  2018cites this paper
• In Silico Implementation of Evolutionary Paradigm in Therapy Design: Towards Anti-Cancer Therapy as Darwinian Process.

  2018cites this paper
• Investigating mechanisms of angiogenesis in health and disease using zebrafish models

  2018cites this paper
• The low affinity neurotrophin receptor CD271 regulates phenotype switching in melanoma

  2017cites this paper
• Long noncoding RNAs in normal and pathological pluripotency.

  2017cites this paper
• Dual addressing of thymidine synthesis pathways for effective targeting of proliferating melanoma

  2017cites this paper
• Decoding transcriptional states in cancer.

  2017cites this paper
• Clinical aspects of molecular profiles in metastatic malignant melanoma

  2017cites this paper
• Toward understanding of the role of reversibility of phenotypic switching in the evolution of resistance to therapy

  2017cites this paper
• The Birth of Malignancy: Embryogenesis and Melanoma

  2017cites this paper
• A tyrosinase-triggered oxidative reaction-based “Turn-on” fluorescent probe for imaging in living melanoma cells

  2017cites this paper
• Interleukin-like EMT inducer regulates partial phenotype switching in MITF-low melanoma cell lines

  2017cites this paper
• Phenotype-based variation as a biomarker of sensitivity to molecularly targeted therapy in melanoma.

  2017cites this paper
• Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma

  2017cites this paper
• Trabectedin is a promising antitumor agent potentially inducing melanocytic differentiation for clear cell sarcoma

  2017cites this paper
• The efficacy and safety of selumetinib in patients with cutaneous melanoma : a meta-analysis of three randomized controlled trials

  2017cites this paper
• Functional Analysis of glioma-associated homolog 1 in maintaining invasive and mesenchymal-like properties of melanoma cells

  2017cites this paper
• Much more than you expected: The non-DHFR-mediated effects of methotrexate.

  2017cites this paper
• Reprogramming human A375 amelanotic melanoma cells by catalase overexpression: Reversion or promotion of malignancy by inducing melanogenesis or metastasis

  2016cites this paper
• Directed Dedifferentiation Using Partial Reprogramming Induces Invasive Phenotype in Melanoma Cells

  2016cites this paper
• Targeting the epigenetics of the DNA damage response in breast cancer

  2016cites this paper
• Lebein, a Snake Venom Disintegrin, Induces Apoptosis in Human Melanoma Cells

  2016cites this paper
• NK Cells, Tumor Cell Transition, and Tumor Progression in Solid Malignancies: New Hints for NK-Based Immunotherapy?

  2016cites this paper
• Are Human Tyrosinase and Related Proteins Suitable Targets for Melanoma Therapy?

  2016cites this paper
• The role of phenotypic plasticity in the escape of cancer cells from targeted therapy.

  2016cites this paper
• Immunogenic, cellular, and angiogenic drivers of tumor dormancy‐a melanoma view

  2016cites this paper
• The role of MITF in autophagy regulation in melanoma

  2016cites this paper
• Study of selected phenotype switching strategies in time varying environment

  2016cites this paper
• Tumor suppressor SET9 guides the epigenetic plasticity of breast cancer cells and serves as an early-stage biomarker for predicting metastasis

  2016cites this paper
• Mg(II)-Catechin nanoparticles delivering siRNA targeting EIF5A2 inhibit bladder cancer cell growth in vitro and in vivo.

  2016cites this paper
• New Functional Signatures for Understanding Melanoma Biology from Tumor Cell Lineage-Specific Analysis

  2015cites this paper
• The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors

  2015cites this paper
• Investigating the effects of Wnt/β-catenin Signalling on Melanoma Cell Metabolism and Mitochondrial Dynamics

  2015cites this paper
• The UPs and DOWNs of MITF in melanoma resistance

  2015cites this paper
• Extravascular Red Blood Cells and Hemoglobin Promote Tumor Growth and Therapeutic Resistance as Endogenous Danger Signals

  2015cites this paper
• Stem cell state and the epithelial‐to‐mesenchymal transition: Implications for cancer therapy

  2015cites this paper
• Other targeted drugs in melanoma.

  2015cites this paper
• Lineage factors and differentiation states in lung cancer progression

  2015cites this paper
• Loss of CITED1, an MITF regulator, drives a phenotype switch in vitro and can predict clinical outcome in primary melanoma tumours

  2015cites this paper
• The MITF family of transcription factors: Role in endolysosomal biogenesis, Wnt signaling, and oncogenesis.

  2015cites this paper
• MITF drives endolysosomal biogenesis and potentiates Wnt signaling in melanoma cells

  2015cites this paper
• In-depth genomic data analyses revealed complex transcriptional and epigenetic dysregulations of BRAFV600E in melanoma

  2015cites this paper
• Chromatin-Remodelling Complex NURF Is Essential for Differentiation of Adult Melanocyte Stem Cells

  2015cites this paper
• microRNA-155, Induced by Interleukin-1ß, Represses the Expression of Microphthalmia-Associated Transcription Factor (MITF-M) in Melanoma Cells

  2015cites this paper
• Adaptive stress signaling in targeted therapy resistance in cancer

  2015cites this paper
• Game of isoforms: PI3K β‐sparing inhibitor is coming

  2015cites this paper
• Phenotype Switching in Melanoma: Implications for Progression and Therapy

  2015cites this paper
• Pro-survival role of MITF in melanoma.

  2015cites this paper
• Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state

  2015cites this paper